Journal Mobile Options
Table of Contents
Vol. 67, No. 3-4, 2004
Issue release date: November 2004

A Study of Pegylated Liposomal Doxorubicin in Platinum-Refractory Epithelial Ovarian Cancer

Wilailak S. · Linasmita V.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: The purposes of this study were to determine the efficacy of pegylated liposomal doxorubicin (PLD), using a dose of 40 mg/m2 given every 3 weeks, in the treatment of platinum-refractory epithelial ovarian cancer (EOC) and to evaluate the toxicities. Methods: Fourteen patients with platinum-resistant EOC were treated with intravenous PLD 40 mg/m2 every 3 weeks. Tumor responses were assessed every 2–3 cycles by CT scan. Results: All 14 patients were evaluable for toxicity, but only 13 patients were evaluable for response because 1 patient who had grade 3 palmar-plantar erythrodysesthesia (PPE) refused to continue with the treatment. Three partial responses were observed in 13 patients. The overall response rate was 23% (95% confidence interval 10–38%). The median time to response was 2 months, and the median duration of response was 3 months. The median survival of the 13 patients was 14.5 months, and the median progression-free survival was 6 months. In this study, we had only 4 cases of grade 3 toxicity (2 cases of grade 3 leukopenia and 2 cases of grade 3 PPE). All toxicities that occurred were manageable. Conclusion: This is the first report of the use of a slightly modified dose schedule for PLD at a dose of 40 mg/m2 every 3 weeks, which is active in platinum-refractory EOC with manageable toxicities.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999;49:33–64.
  2. Seewaldt VL, Greer BE, Cain JM, et al: Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial. Am J Obstet Gynecol 1994;170:1666–1670.
  3. Neijt JP, ten Bokkel Huiniuk WW, van der Berg ME: Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991;27:1367–1372.
  4. Lasic DD: Doxorubicin in sterically stabilized liposomes. Nature 1996;380:561–562.
  5. Muggia FM, Hainsworth ID, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987–993.
  6. Israel VP, Garcia AA, Roman L, et al: Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 2000;78:143–147.
  7. Hensley ML, Hoppe B, Leon L, et al: The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecol Oncol 2001;82:464–469.
  8. Safra T, Groshen S, Jeffers S, et al: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: Analysis of toxicities and predictors of outcome. Cancer 2001;91:90–100.
  9. Markman M, Kennedy A, Webster K, et al: Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000;78:369–372.
  10. Gordon AN, Granai CO, Rose PG, et al: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000;18:3093–3100.
  11. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, World Health Organization, 1979.
  12. Markman M, Reichman B, Hakes T, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9:1801–1805.
  13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.

    External Resources

  14. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346–353.
  15. Omura GA, Bundy BN, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989;7:457–465.
  16. A’Hern RP, Gore ME: Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995;13:726–732.
  17. Stebbing J, Gaya A: Pegylated liposomal doxorubicin (CaelyxTM) in recurrent ovarian cancer. Cancer Treatment Rev 2002;28:121–125.
  18. Maluf FC, Spriggs D: Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol 2002;85:18–31.
  19. Williams CJ, Stewart L, Parmar M, et al: Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group. Semin Oncol 1992;19(1 suppl 2):120–128.
  20. Conte PF: Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma. Bull Cancer 1993;80:152–155.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00